2024-11-15 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Comparison and Alpha/Beta Analysis:**

Pfizer Inc. (PFE) is a multinational pharmaceutical corporation that develops and manufactures medicines and vaccines. 

As of the last data point, PFE's cumulative return is 8.86%, significantly lagging behind the S&P 500 (VOO) with a return of 179.47%. This results in a **negative divergence of -170.61**, placing PFE at the **1.01 percentile** of its historical range compared to VOO. 

The provided alpha/beta analysis reveals PFE's performance relative to the market:

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.9% | 17.4% | -9.5% | 0.8 | 194.7 |
| 2016-2018  | 52.6% | 17.4% | 20.3% | 0.8 | 234.7 |
| 2017-2019  | 32.5% | 21.8% | -19.2% | 0.8 | 210.7 |
| 2018-2020  | 19.0% | 31.4% | -28.3% | 0.7 | 208.6 |
| 2019-2021  | 61.4% | 31.4% | -38.6% | 0.6 | 334.6 |
| 2020-2022  | 54.1% | 28.6% | 30.5% | 0.6 | 290.4 |
| 2021-2023  | -12.3% | 47.0% | -47.2% | 0.4 | 163.2 |
| 2022-2024  | -46.0% | 44.6% | -76.4% | 0.5 | 148.4 |

PFE has consistently exhibited **lower alpha values**, indicating underperformance compared to the S&P 500, particularly in recent years. The beta values suggest PFE's volatility is generally **lower than the market**.

**2. Recent Price Movement:**

* Closing price: 26.72 
* Last market price: 26.33 
* 5-day moving average: 26.58
* 20-day moving average: 27.7
* 60-day moving average: 28.35

The recent price action suggests **short-term bearish momentum**. The closing price is below both the 5-day and 20-day moving averages, and the 60-day moving average is further ahead.

**3. Technical Indicators and Expected Return:**

* RSI: 32.0 - indicating **oversold conditions**.
* PPO: -0.54 - suggesting **weak momentum**.
* Recent (20-day) Relative Divergence Change: -0.39 (-), indicative of **short-term downward pressure**.
* Expected Return: 0.0% -  over the long term (2+ years) based on current conditions, PFE is expected to **yield returns similar to the S&P 500**.

**4. Recent Earnings Performance and Forecast:**

| Date         | EPS  | Expected EPS |
|--------------|------|--------------|
| 2024-10-29  | 1.06 | 0.614         |
| 2024-07-30  | 0.6  | 0.458         |
| 2024-05-01  | 0.82 | 0.516         |
| 2024-01-30  | 0.1  | -0.19         |
| 2023-10-31  | -0.17 | -0.32         |

The most recent earnings report for the quarter ending October 29th, 2024, showed an EPS of 1.06, exceeding the expected EPS of 0.614.  This **positive earnings surprise** could potentially fuel a short-term uptick in price.

**5. Financial Information Analysis:**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|---------|--------------|
| 2024-09-30  | $17.70B | 70.27%        |
| 2024-06-30  | $13.28B | 75.16%        |
| 2024-03-31  | $14.88B | 77.29%        |
| 2023-12-31  | $14.25B | 46.92%        |
| 2023-09-30  | $13.49B | 31.30%        |

PFE has experienced a **consistent revenue growth** trend over the past year, with the most recent quarter (ending September 30th, 2024) reaching $17.70B in revenue. 
The **profit margins have been highly variable**, with the most recent quarter showing a significant improvement compared to the previous quarters.

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|---------|---------|
| 2024-09-30  | $92.29B | 4.84%   |
| 2024-06-30  | $87.70B | 0.05%   |
| 2024-03-31  | $92.28B | 3.38%   |
| 2023-12-31  | $89.01B | -3.78%  |
| 2023-09-30  | $96.93B | -2.46%  |

The ROE (Return on Equity) has been **fluctuating**, with a recent positive trend. This suggests PFE's ability to utilize its equity to generate profits is improving.

**6. News and Recent Issues:**

* **Recent Earnings News:**  Based on recent news reports from Shacknews, PFE's most recent earnings announcement exceeded expectations.
* **Recent Market Outlook:** Analyst opinions on PFE vary, with some expressing cautious optimism and others expecting continued volatility due to factors like competition and market dynamics. 
* **Performance Highlights:**  Finbold reports PFE's performance has been impacted by the decline in COVID-19 vaccine sales. However,  the company is focusing on expanding its pipeline in other therapeutic areas, which could potentially drive future growth.

**7. Comprehensive Analysis:**

PFE currently faces a challenging market environment with its stock significantly underperforming the broader market (S&P 500). The recent earnings announcement, however, provides some positive momentum. While the company's historical alpha values suggest potential underperformance, its consistent revenue growth and improving profitability trends may indicate a potential for turnaround.

**8. Recommendations:**

- **Short-term:** PFE's current price action suggests short-term bearish momentum. Investors should monitor the company's future earnings reports closely to gauge its potential for recovery.
- **Long-term:** PFE's long-term expected return is similar to the S&P 500.  Investors who are seeking long-term growth potential should consider investing in companies with a stronger track record of outperformance. 
- **Diversification:** As with any investment, diversification is key. Investors should consider spreading their portfolio across different asset classes and sectors to mitigate risk.

**Disclaimer:** This analysis is based on publicly available information and does not constitute financial advice. Investors should conduct their own thorough research and consult with a qualified financial professional before making any investment decisions.